Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients

From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure. The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients. The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.

NCT Number	NCT05586867
Lead Sponsor	GCS Ramsay Santé pour l'Enseignement et la Recherche Collaborators: European Clinical Trial Experts Network
Conditions	Iron Metabolism Disorders, Calcium Phosphate Metabolism, Hepatic Metabolic Disorders, Hemodialysis Complication
Enrollment	200 participants
Start Date	2021-12-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2031-12-01 (estimated)
Updated on ClinicalTrials.gov	2022-10-19